advertisement
Trabecular meshwork (TM) cells are now considered to play an active role in the aqueous outflow mechanism because they exhibit smooth muscle-like contractile properties. Endothelin-1 (ET-1), a potent vasoconstrictor peptide, has been proposed to play a role in the local regulation of aqueous outflow and intraocular pressure (IOP) control. We propose an in vitro culture model as a method for the study of ET-1-induced human TM (HTM) cell contractility and for the study of whether pre-incubation with flunarizine, a calcium-channel blocker, can inhibit the action of ET-1. Experiments were performed on semiconfluent HTM cells (primary cultures established from normotensive human donor eyes) at the second passage, with phosphate-buffered saline (PBS) as a control. The contractile status of the cells was evaluated by a morphometric analysis of cell area, assuming that HTM cells in culture are able to reduce their area as a consequence of cytoskeletal contraction, rather than regulatory volume decrease. After incubation with 10 μM ET-1 for 5 mins, we observed a reduction of HTM cell area with respect to PBS-treated cells: 2425 ± 876 μm2 versus 3125 ± 987 μm2 (P < 0.001); and cells exhibited a retraction in shape and a reduction in number of indented profiles. Administration of ET-1 at progressively lower doses produced a corresponding lower reduction of HTM cell area, suggesting a dose-response effect of ET-1. Pre-incubation with 10 μM flunarizine strongly inhibited the ET-1 effect on HTM cell contraction: 2806 ± 865 μm2 versus 2910 ± 846 μm2 (P = not significant). Our data indicate that ET-1 induced a statistically significant reduction in the area of HTM cells versus controls, and that ET-1 can directly influence the aqueous outflow. Moreover, we observed that flunarizine inhibited the effect of ET-1 on the HTM cells.
Dr. M. Cellini, Department of Surgery and TransplantSection Ophthalmology I, Alma Mater Studiorum University of Bologna, Via Massarenti, 9, I40138 Bologna, Italy. mauro.cellini@unibo.it
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)